In clinical trials of Wegovy (a semaglutide medication), participants lost an average of 15% of their body weight (approximately 33 pounds, though individual results varied) within 68 weeks
By mimicking the gut hormone GLP1, it enhances insulin release, suppresses glucagon, and delays stomach emptyingso your brain registers fullness sooner and you physically eat less
Bowel Obstruction (Ileus) Bowel obstructions are intestinal blockages in the large intestine and colon
For instance, in the SURPASS trials 1 , patients taking tirzepatide experienced up to 20.2% body weight reduction , compared to around 13.7% for semaglutide
Tracking sheets for researchers managing multiple peptides If you are researching semaglutide alongside other compounds, keeping track becomes even more critical
There is limited clinical data on split dosing